The transcriptome and metabolome analyses to all samples were reached the basic standards of quality control. An average 50 million clean reads from each sample were acquired with Q30 >93%. And more than 93% acquired clean reads of each sample library were successfully mapped in the reference genomes (Additional file 1).
Principal components analyses (PCA) weakly resolved the transcriptome and the metabolome profiles in grape cell samples which treated with different endophytic fungal strains or their corresponding extracts (Fig. 1). Replicates of one treatment could almost grouped together in PCA plots based on either transcripts or metabolites profiles in grape cells (Fig. 1). For PCA of transcriptome, PC1 could well resolve sample groups C11 (grape cells treated with endophytic fungal strain C11, and the same of R12 and R32) and R32 with other sample groups except group R12E (grape cells treated with extract of endophytic fungal strain R12, and the same as C11E and R32E). Whereas, PC2 obviously resolved group R32 from other groups except group R32E. Group R12 was closely joined to the group C11E and these groups together could be divided from the groups R32E and R12, in this PCA analysis (Fig. 1 left). Groups R32E and C11E closely joined to the control group in transcriptome PCA plot, due to their similar transcripts profiles (Fig. 1 left). For metabolome assay, a group of mixed samples was randomly added as quality control (QC) during the process of analysis, and all replicates of these QC samples were well clustered together, and located almost within the middle of other sample groups, implicated the validation of the metabolome analysis (Fig. 1 right). In the metabolome PCA, PC1 could resolve group C11 with other groups, while PC2 resolved groups R12, R12E from groups C11, R32 and other groups (Fig. 1 right). Besides, sample groups R12 and R12E were observed close together in PCA plots of both transcriptome and metabolome analysis (Fig. 1). Similar to the transcriptomic assay, groups R32E and C11E were also closely joined to the control group in the PCA of metabolome (Fig. 1 right).
As have compared to the corresponding controls, the counts of differentially expressed genes (DEGs,) and differentially regulated metabolites (DRMs) were summarized in Figure 2. For most of the treatments, more counts of DEGs and DRMs were triggered in living fungi exposed grape cells than that of their corresponding fungal extracts treated grape cells (Fig. 2). For living fungi treatments, fungal strains initiated counts of DEGs in grape cells from the most to the least were C11> R32 > R12 in transcriptomic analysis (Fig. 2 A-C). Whereas in metabolome assay, the used living fungal strains triggered DRMs counts in grape cells from the most to the least were R12>C11>R32 (Fig. 2 E-F). Regardless the treatments with living fungi or fungal extracts in transcriptome analysis, more proportions of DEGs in grape cells were down regulated (Fig. 2 A-C). For metabolome assay, all living fungi treatments exclusively initiated greater counts of DRMs in grape cells than those triggered by fungal extracts (Fig. 2 D-F). And those living fungi treatments also tend to cause more proportions of down regulated DRMs in grape cells (Fig. 2 D-F).
The exposure to different living fungi and soluble extracts from different fungal strains resulted in different proportions of specific responses in DEGs and DRMs counts (Fig. 3). In transcriptome assay, dual culture with fungal strains C11, R12 and R32 initiated 49.5%, 28.1% and 44.7%, respectively the specific DEGs counts in grape cells. And the proportions of co-detected DEG counts in these fungal strains treated grape cells were 8.7%, 29.7% and 10.9%, respectively. Beside the treatment of R12, treatments with other two fungal strains C11 and R32 initiated smaller proportions of co-detected DEGs than that of the specific ones(Fig. 3 up-left). As for fungal extract treatments, the proportions of specific DEGs in C11E, R12E and R32E treated grape cells were 57.4%, 75.6% and 27.0%, respectively, while the proportions of the co-detected DEGs in these fungal extracts exposed grape cells were only 12.8%, 1.2% and 3.9%, respectively (Fig. 3 up-right). And in metabolome analysis, exposure to fungal strains C11, R12 and R32 caused 44.4%, 48.8% and 30.8%, respectively the specific DRMs in grape cells, and the proportions of specific DRMs in C11E, R12E and R32E treated grape cells were 11.1%, 60.7% and 28.6%, respectively (Fig. 3 below). The exposure to fungal extracts C11E and R32E initiated greater proportions (77.8% and 50% respectively) of co-detected DRMs in grape cells (Fig. 3). Whenever in transcriptome or in metabolome assays, R12E were all triggered greatest proportions of specific responses of DEGs and DRMs counts in grape cells (Fig. 3).
However, when concerning the treatment pairs (one treatment pair was defined as the treatments of living fungus and the corresponding fungal extract), major proportions of responses of DEGs and DRMs in fungal extracts exposed grape cells were encompassed within the corresponding living fungi triggered DEGs and DRMs in grape cells, with the only exception of treatment pair R12 and R12E in transcriptomic assay (Fig. 4). In transcriptome analysis, in total 70.2 % and 73.7% DEGs in C11E and R32E treated grape cells were detected respectively, within the C11 and R32 treated grape cells (Fig. 4). One exception was that only 22.2% DEGs in R12E treated grape cells were co-detected in the corresponding living fungus (R12) treated grape cells (Fig. 4). Meanwhile, 88.9%, 75% and 71.4% DRMs in C11E, R12E and R32E treated grape cells, were detected simultaneously in C11, R12 and R32 dual cultured grape cells respectively, in the metabolome analysis (Fig. 4).
All those significant DEGs were subjected to Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The significantly enriched GO function terms and KEGG pathways in grape cells which initiated by fungi and fungal extracts were greatly dependent upon the used endophytic fungal strains (Fig. 5). For treatment pair C11 and C11E, the exposure to living fungal strain C11 significantly enriched more GO function terms in the biological processes (BP), cellular components (CC) and molecular functions (MF) in grape cells, while in C11E treated grape cells enriched almost no significant GO terms in BP and CC functions (Fig. 5). However, GO terms in MF which associate the functions of DNA binding transcription factor activity (DBTFA), transcription regulator activity (TRA) and oxidoreductase activity (ORA) in C11E treated grape cells were significantly enriched, and these GO terms were also significantly enriched in C11 exposed grape cells (Fig. 5). Besides, GO terms in MF category of DBTFA and TRA were also detected the significant enrichments in R12E and R32 treated grape cells (Fig. 5). Different to the treatment pair C11 and C11E, the R12 exposure almost caused no significant GO term enrichment in grape cells, while several GO terms in categories BP, CC and MF were significantly enriched in R12E exposed grape cells (Fig. 5). For treatment pair R32 and R32E became another story. Living fungal strain R32 dual cultured grape cells enriched great amounts of significant GO terms in categories of BP, CC and MF, and some of the significantly enriched GO terms in BP and MF were also detected the enrichment in R32E treated grape cells (Fig. 5).
In KEGG enrichment analysis, the significant enriched KEGG signal pathways in this experiment were fell into plant hormone signal transduction, photosynthesis, cyanoamino acid metabolism, flavonoid biosynthesis, plant Circadian rhythm, pentose and glucoronate interconversions, phenylpropanoid biosynthesis and plant-pathogen interaction(Fig. 6). And KEGG pathways of plant hormone signal transduction and photosynthesis were significant enriched in grape cells of most the treatments in this experiment (Fig. 6). Nevertheless, most of the enriched KEGG pathways in grape cells which enriched in fungal extracts treated grape cells were also comprised within their corresponding living fungi exposed grape cells (Fig. 6). However, the significant enriched KEGG pathways in fungi and fungal extracts exposed grape cells were greatly varied from one fungal strain to another (Fig. 6).
As comparing the enriched GO terms and KEGG pathways in those treatment pairs, almost all those enriched GO terms and KEGG pathways in C11E and R32E exposed grape cells were included within those of the corresponding fungal strains C11 and R32 treated grape cells (Fig. 7). Even the treatment pair R12E and R12, major proportions of enriched GO terms and KEGG pathways (47.4 % and 76.1%, respectively) in R12E treated grape cells were comprised in that of the R12 exposed grape cells (Fig.7), regardless the lowest (22.2%) co-detected DEGs in R12E and R12 treated grape cells (Fig. 3).
DEGs which involved in significant co-enriched GO terms and KEGG pathways were summarized in Table 1 and Table 2, respectively. The more or less significantly enriched specific GO terms or KEGG pathways in living fungal treated grape cells could also be significantly enriched in the corresponding fungal extracts treated grape cells (Table 1 and Table 2). Such enriched specific GO terms as GO:0008017 (microtubule binding), GO:0015631(tubulin binding) and GO:0046527 (glucosyltransferase activity) in R12 and R12E treated grape cells, and GO:0005618 (cell wall), GO:0005576 (extracellular region), GO:0030312 (external encapsulating structure) and GO:0071944 (cell periphery) in R32 and R32E exposed grape cells (Table 1). As well as the significant enriched fungal strain-specific KEGG pathways as vvi04016 (MAPK signaling pathway—plant) in C11/C11E, vi03030 (DNA replication) in R12/R12E and vvi04626 (Plant-pathogen interaction) in R32/R32E treated grape cells, respectively (Table 2). Beside the treatment pair R12 and R12E, more counts of DEGs which involved in certain GO function terms or KEGG pathways were enriched in living fungi treated grape cells than that of the fungal extracts exposed grape cells (Table 1 and Table 2). However, despite the differences of total counts of DEGs enriched in certain GO terms or KEGG pathways, the ratio of up/down regulated DEGs in certain GO terms or KEGG pathways maintained a similar trends between living fungi and the corresponding fungal extracts treated grape cells (Table 1 and Table 2).
Table 1. Comparison of the differentially expressed genes (DEGs) involved in the significant co-enriched gene ontology (GO) terms in living fungi and fungal extracts treated grape cells
GO ID
|
All
counts
|
Up
regulated
|
Down
regulated
|
All
counts
|
Up
regulated
|
Down
regulated
|
|
C11
|
C11E
|
GO:0003700
|
102
|
19
|
83
|
35
|
1
|
34
|
GO:0140110
|
104
|
19
|
85
|
35
|
1
|
34
|
|
R12
|
R12E
|
GO:0048046
|
10
|
1
|
9
|
13
|
0
|
13
|
GO:0003700
|
43
|
11
|
32
|
80
|
9
|
71
|
GO:0008017
|
12
|
12
|
0
|
20
|
20
|
0
|
GO:0140110
|
44
|
11
|
33
|
82
|
9
|
73
|
GO:0015631
|
12
|
12
|
0
|
20
|
20
|
0
|
GO:0016762
|
10
|
1
|
9
|
13
|
0
|
13
|
GO:0046527
|
17
|
3
|
14
|
24
|
4
|
20
|
|
R32
|
R32E
|
GO:0048046
|
17
|
1
|
16
|
6
|
0
|
6
|
GO:0005618
|
24
|
1
|
23
|
7
|
0
|
7
|
GO:0005576
|
17
|
1
|
16
|
6
|
0
|
6
|
GO:0030312
|
24
|
1
|
23
|
7
|
0
|
7
|
GO:0071944
|
30
|
3
|
27
|
10
|
0
|
6
|
GO:0003700
|
74
|
16
|
58
|
33
|
2
|
31
|
GO:0140110
|
75
|
16
|
59
|
33
|
2
|
31
|
GO:0016762
|
17
|
1
|
16
|
6
|
0
|
6
|
Table 2. Comparison of the differentially expressed genes (DEGs) involved in the significant co-enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in living fungi and fungal extracts treated grape cells
KEGG ID
|
All
counts
|
Up
regulated
|
Down
regulated
|
All
counts
|
Up
regulated
|
Down
regulated
|
|
C11
|
C11E
|
vvi04075
|
72
|
23
|
49
|
24
|
4
|
20
|
vvi04016
|
37
|
15
|
22
|
14
|
4
|
10
|
|
R12
|
R12E
|
vvi04075
|
31
|
6
|
25
|
50
|
13
|
37
|
vvi03030
|
11
|
11
|
0
|
17
|
17
|
0
|
|
R32
|
R32E
|
vvi04075
|
45
|
19
|
26
|
10
|
5
|
5
|
vvi04626
|
33
|
11
|
22
|
11
|
2
|
9
|
In metabolome analysis, DRMs in different fungi and fungal extracts treated grape cells were also performed the KEGG analyses. Dual cultivation with living fungi C11, R12 and R32 enriched 18, 2 and 3 specific KEGG pathways, respectively in grape cells, with 12 KEGG pathways which have co-enriched in all these fungi treated grape cells (Fig. 8). For the treatments of fungal extracts from different fungal strains, 5 and 3 specific KEGG pathways were enriched in R12E and R32E exposed grape cells. No significant specific KEGG pathways were enriched in C11E treated grape cells. And as concerning the treatment pairs however, 100%, 73.3% and 92.3% KEGG pathways enriched in C11E, R12E and R32E treated grape cells were enriched simultaneously in C11, R12 and R32 treated grape cells (Fig. 8).
Table 3 listed the differential regulated metabolites (DRMs) in the metabolome analysis with the threshold as Log2 (Fold. Change) ≥1.0, and VIP ≥1.0 (Table 3). The exposure to fungus C11 and its extracts more possibly influenced metabolites in compound class of amino acids and derivatives, while exposed to fungus R12 and its extract (R12E) initiated more metabolites changes in classes of glycerol ester, lysophosphatidylcholine (LPC) and lysophosphatidyl ethanolamine (LPE) (Table 3). And other classes of metabolites could be influenced more or less by most of the treatments in this metabolome assay (Table 3). In most cases, co-regulated metabolites in living fungi or the corresponding fungal extracts treated grape cells maintained the same trends of up or down regulations. It deserve to note that the metaboliteε-Viniferin was up regulated in living fungi treated grape cells, while this compound was greatly down regulated in fungal extracts treated grape cells (Table 3).
Table 3. Significant regulated metabolites in grape cells after the treatment with different endophytic fungi and fungal extracts.
Class a
|
Significant changed compounds
|
Log (Fold change)
|
C11
|
C11E
|
R12
|
R12E
|
R32
|
R32E
|
Alkaloids
|
Caffeine
|
|
|
-1.12
|
|
-10.9
|
-1.09
|
AA
|
5-Aminovaleric acid
|
-1.30
|
|
|
|
|
|
Trans-4-Hydroxy-L-proline
|
-1.15
|
|
|
|
|
|
L-Tyramine
|
-3.16
|
-1.65
|
-2.17
|
-4.06
|
-4.07
|
-14.68
|
1,2-N-Methylpipecolic acid
|
-1.18
|
|
|
|
|
-1.01
|
N-Acetyl-L-leucine
|
2.43
|
|
|
|
|
|
N-Acetylaspartate
|
1.40
|
|
|
|
|
|
N-Acetyl-L-glutamic acid
|
1.23
|
|
|
|
|
|
N-Acetylmethionine
|
-1.79
|
-1.28
|
-1.30
|
-1.87
|
-2.84
|
-4.95
|
N-(3-Indolylacetyl)-L-alanine
|
|
|
1.40
|
|
|
|
L-Homocystine
|
|
|
-1.04
|
|
|
|
Leucylphenylalanine
|
|
|
-1.24
|
|
|
|
L-Glutamic acid O-glycoside
|
|
|
|
-2.98
|
-4.31
|
|
N-α-Acetyl-L-arginine
|
2.02
|
|
|
|
|
|
N-Acetyl-L-tyrosine
|
4.55
|
|
|
|
|
|
Lysine butyrate
|
-1.60
|
-1.18
|
|
|
|
|
N-(3-Indolylacetyl)-L-alanine
|
3.40
|
|
|
|
|
|
Leucylphenylalanine
|
-1.30
|
|
|
|
|
|
L-Glutaminyl-L-valyl-L-valyl-L-cysteine
|
8.90
|
|
8.34
|
8.82
|
1.01
|
|
Anthraquinone
|
6-Hydroxyrumicin-8-O-D-glucopyranoside
|
1.85
|
|
|
|
1.01
|
|
Coumarins
|
Skimmin
|
1.82
|
|
|
|
1.23
|
|
Dihydroflavone
|
Eriodictyol 7-O-glucoside
|
|
|
1.60
|
1.12
|
|
|
Hesperetin 7-O-neohesperidoside(Neohesperidin)
|
-15.6
|
-2.09
|
-6.64
|
-15.6
|
|
-15.6
|
Flavonols
|
Isorhamnetin-3-O-β-D-glucoside
|
|
|
1.24
|
|
|
|
FFA
|
13-HOTrE(r)
|
|
|
1.06
|
|
|
|
γ-Linolenic Acid
|
|
|
|
-1.02
|
|
|
11-Octadecanoic acid(Vaccenic acid)
|
1.40
|
|
|
|
|
|
Glycerol ester
|
1-α-Linolenoyl-glycerol*
|
|
|
-1.00
|
|
|
|
LPC
|
LysoPC 18:1
|
|
|
1.13
|
|
|
|
LysoPC 18:1(2n isomer)
|
|
|
1.23
|
|
|
|
LysoPC 18:0
|
|
|
1.01
|
1.11
|
|
|
LysoPC 18:0(2n isomer)
|
|
|
|
1.03
|
|
|
LPE
|
LysoPE 16:0
|
|
|
1.89
|
1.74
|
|
|
LysoPE 16:0(2n isomer)
|
|
|
1.63
|
1.73
|
|
|
LysoPE 18:3
|
|
|
|
|
-9.51
|
|
LysoPE 18:2
|
|
|
1.56
|
1.46
|
|
|
LysoPE 18:2(2n isomer)
|
|
|
1.61
|
1.29
|
|
|
LysoPE 18:1
|
|
|
1.90
|
1.54
|
-8.57
|
|
LysoPE 18:1(2n isomer)
|
|
|
1.48
|
1.10
|
|
|
Class
|
Significant changed Compounds
|
Log (Fold Change)
|
C11
|
C11E
|
R12
|
R12E
|
R32
|
R32E
|
ND
|
5-Methylcytosine
|
-1.40
|
|
|
|
|
|
Xanthine
|
-1.22
|
|
|
|
|
|
9-(β-D-Arabinofuranosyl)hypoxanthine
|
|
|
1.01
|
|
|
|
Organic acids
|
6-Aminocaproic acid
|
-1.21
|
|
|
|
|
|
2-Furanoic acid
|
|
|
|
|
-1.49
|
|
3-Hydroxy-3-methyl butyric acid
|
|
|
|
|
1.06
|
|
Diethyl phosphate
|
|
|
-1.51
|
|
|
|
3-Hydroxyanthranilic acid
|
-9.61
|
|
|
|
|
|
Others
|
Octadecenoic amide
|
|
|
2.05
|
|
|
|
Propyl2-(trimethylammonio)ethyl phosphate
|
1.52
|
|
1.68
|
|
|
|
α-Viniferin
|
-11.2
|
-1.67
|
2.03
|
-11.2
|
-1.52
|
-2.47
|
PC
|
Choline alfoscerate
|
|
|
|
|
|
-2.25
|
PA
|
3,4-Dihydroxybenzeneacetic acid
|
|
|
1.15
|
|
|
|
Trans-4-Hydroxycinnamic Acid Methyl Ester
|
|
|
-1.24
|
|
|
|
3,4-Dihydroxybenzeneacetic acid
|
1.21
|
|
|
|
|
|
Methyl ferulate
|
1.53
|
|
|
1.18
|
1.44
|
1.78
|
Isosalicylic acid O-glycoside
|
|
|
|
|
1.32
|
|
3-Hydroxy-5-Methylphenol-1-Oxy-β-D-Glucose
|
|
|
|
1.04
|
|
|
Feruloylmalic acid
|
1.87
|
|
1.56
|
1.16
|
2.78
|
1.81
|
3-Hydroxy-4-isopropylbenzylalcohol 3-glucoside
|
|
1.07
|
1.04
|
1.15
|
1.61
|
|
1'-O-Vanilloyl-β-D-glucoside
|
|
|
|
1.14
|
|
|
Syringic acid O-glucoside
|
|
|
-1.06
|
|
1.08
|
|
Trihydroxycinnamoylquinic acid
|
1.08
|
|
-9.22
|
|
1.61
|
-9.22
|
Syringin
|
|
|
1.18
|
1.14
|
1.95
|
|
p-Coumaroylcaffeoyltartaric acid
|
3.32
|
|
|
|
1.57
|
|
Plumerane
|
Indole
|
-1.11
|
|
|
|
|
|
SA
|
D-Glucoronic acid
|
-1.73
|
|
|
-1.18
|
|
|
|
D-(+)-Melezitose*
|
|
|
1.28
|
|
|
|
|
D(+)-Melezitose O-rhamnoside
|
1.38
|
|
1.38
|
|
|
|
Stilbene
|
Piceid
|
1.31
|
|
1.70
|
1.63
|
2.03
|
|
ε-Viniferin
|
1.25
|
-9.22
|
2.61
|
-9.22
|
|
-9.22
|
Resveratrol-O-diglucoside
|
|
|
|
|
-1.25
|
|
Tannin
|
2-O-Galloyl-β-D-glucose
|
|
|
-1.80
|
1.93
|
1.23
|
-1.03
|
Triterpene
|
Camaldulenic acid
|
-10.9
|
1.28
|
-10.9
|
-10.9
|
-10.9
|
-10.9
|
2-Hydroxyoleanolic acid
|
-2.78
|
1.34
|
-3.05
|
-3.06
|
-1.82
|
-3.59
|
Vitamin
|
Nicotinamide
|
|
|
|
|
-1.01
|
|
Pyridoxine
|
|
|
1.01
|
|
|
|
AA: Amino acids and derivatives; FFA: Free fatty acid; LPC: Lysophosphatidylcholine; LPE: Lysophosphatidyl ethanolamine; ND: Nucleotides and derivatives; PC: Choline alfoscerate; PA: Phenolic acids; SA: Saccharides and Alcohols.